Cited 33 times in
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2020-12-01T16:55:27Z | - |
dc.date.available | 2020-12-01T16:55:27Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180047 | - |
dc.description.abstract | Introduction: In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We now report final OS and updated safety data. Methods: Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among patients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). Secondary endpoints included OS and safety. Results: 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR-/ALK-), and 68 in Cohort 3 (EGFR-/ALK-; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3-24.5) in patients with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6-13.6) in patients with EGFR-/ALK- NSCLC with TC ≥ 25 %, and 13.2 months (5.9-not reached) in patients with EGFR-/ALK- NSCLC with TC ≥ 90 %. Median (95 % CI) OS was slightly shorter in patients with TC < 25 % (9.9 months [4.2-13.3] in patients with EGFR+/ALK+ NSCLC and 9.3 months [5.9-10.8] in those with EGFR-/ALK- NSCLC). Treatment-related adverse events of special interest occurred with similar incidences as reported previously. Conclusions: After additional follow-up, final OS data remain encouraging across all cohorts, further supporting the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with EGFR+/ALK+ tumours. There were no new safety signals. Trial registration: ClinicalTrials.gov NCT02087423. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier Scientific Publishers | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Marina Chiara Garassino | - |
dc.contributor.googleauthor | Byoung-Chul Cho | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Julien Mazières | - |
dc.contributor.googleauthor | Johan Vansteenkiste | - |
dc.contributor.googleauthor | Hervé Lena | - |
dc.contributor.googleauthor | Jesus Corral Jaime | - |
dc.contributor.googleauthor | Jhanelle E Gray | - |
dc.contributor.googleauthor | John Powderly | - |
dc.contributor.googleauthor | Christos Chouaid | - |
dc.contributor.googleauthor | Paolo Bidoli | - |
dc.contributor.googleauthor | Paul Wheatley-Price | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Lynne Poole | - |
dc.contributor.googleauthor | Catherine Wadsworth | - |
dc.contributor.googleauthor | Phillip A Dennis | - |
dc.contributor.googleauthor | Naiyer A Rizvi | - |
dc.identifier.doi | 10.1016/j.lungcan.2020.06.032 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 32702570 | - |
dc.subject.keyword | ATLANTIC | - |
dc.subject.keyword | Durvalumab | - |
dc.subject.keyword | NSCLC | - |
dc.subject.keyword | Overall survival | - |
dc.subject.keyword | Safety | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 147 | - |
dc.citation.startPage | 137 | - |
dc.citation.endPage | 142 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.147 : 137-142, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.